Список літератури, представлений в прототипі клінічної настанови 2 страница

128. Ohkubo T, Imai Y, Tsuji I, Nagai K, Kato J, Kikuchi N, Nishiyama A, Aihara A, Sekino M, Kikuya M, Ito S, Satoh H, Hisamichi S. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens 1998;16:971–975. OS.

129. Zarnke KB, Feagan BG, Mahon JL, Feldman RD. A randomized study com­paring a patient-directed hypertension management strategy with usual office-based care. Am J Hypertens 1997;10:58–67. OS.

130. Pickering T, James GD, Boddie C, Hrashfield GA, Blank S, Laragh JH. How common is white coat hypertension? JAMA 1988;259:225–228. OS.

131. Parati G, Ulian L, Santucci C, Omboni S, Mancia G. Difference between clinic and daytime blood pressure is not a measure of the white coat effect. Hypertension 1998;31:1185–1189. OS.

132. Mancia G, Bertinieri G, Grassi G, Parati G, Pomidossi G, Ferrari A, Gregorini L, Zanchetti A. Effects of blood-pressure measurement by the doctor on patient’s blood pressure and heart rate. Lancet 1983;2: 695–698. OS.

133. Mancia G, Parati G, Pomidossi G, Grassi G, Casadei R, Zanchetti A. Alert­ing reaction and rise in blood pressure during measurement by physician and nurse. Hypertension 1987;9:209–215. OS.

134. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006;47: 846–853. OS.

135. Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Prognosis of masked hypertension and white-coat hypertension detected by 24-h ambulatory blood pressure monitoring. J Am Coll Cardiol 2005;46:508–515. OS.

136. Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension. A 10-year follow-up study. Circula­tion 1998;98:1892–1897. OS.

137. Fagard RH, Staessen JA, Thijs L, Gasowski J, Bulpitt CJ, Clement D, de Leeuw PW, Dobovisek J, Jaaskivi M, Leonetti G, O’Brien E, Palatini P, Parati G, Rodicio JL, Vanhanen H, Webster J. Response to antihyperten-sive treatment in older patients with sustained or nonsustained systolic hypertension. Circulation 2000;102:1139–1144. OS.

138. Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, Menard J, Mallion JM. Cardiovascular prognosis of ‘masked hypertension’ detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004;291:1342–1349. OS.

139. Verdecchia P, Reboldi GP, Angeli F, Schillaci G, Schwartz JE, Pickering TG, Imai Y, Ohkubo T, Kario K. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension 2005;45:203–208. OS.

140. Sega R, Trocino G, Lanzarotti A, Carugo S, Cesana G, Schiavina R, Valagussa F, Bombelli M, Giannattasio C, Zanchetti A, Mancia G. Altera­tions of cardiac structure in patients with isolated office, ambulatory or home hypertension. Data from the general PAMELA population. Circula­tion 2001;104:1385–1392. OS.

141. Wing LMH, Brown MA, Beilin LJ, Ryan P, Reid C. Reverse white-coat hypertension in older hypertensives. J Hypertens 2002;20:639–644. OS.

142. Bjorklund K, Lind L, Zethelius B, Andren B, Lithell H. Isolated ambulat­ory hypertension predicts cardiovascular morbidity in elderly men. Circulation 2003;107:1297–1302. OS.

143. Lurbe E, Torro I, Alvarez V, Nawrot T, Paya R, Redon J, Staessen JA. Prevalence, persistence, and clinical significance of masked hyperten­sion in youth. Hypertension 2005;45:493–498. OS.

144. Mancia G, Parati G. Reactivity to physical and behavioral stress and blood pressure variability in hypertension. In: Julius S, Bassett DR. (editors). Handbook of Hypertension. Vol 9. Behavioral Factors in Hypertension. Elsevier Sci Publ; 1987. pp. 104–122. RV.

145. Pescatello LS, Franklin BA, Fagard R, Farquhar WB, Kelley GA, Ray CA. American College of Sports Medicine Position Stand: Exercise and Hyper­tension. Med Sci Sports Exerc 2004;36:533–553. GL.

146. Singh JP, Larson MG, Manolio TA, O’Donnell CJ, Lauer M, Evans JC, Levy D. Blood pressure response during treadmill testing as a risk factor for new-onset hypertension: the Framingham Heart Study. Circu­lation 1999;99:1831–1836. OS.

147. Carroll D, Smith GD, Shipley MJ, Steptoe A, Brunner EJ, Marmot MG. Blood pressure reactions to acute psychological stress and future blood pressure status: a 10-year follow-up of men in the Whitehall II study. Psychosom Med 2001;63:737–743. OS.

148. Manolio TA, Burke GL, Savage PJ, Sidney S, Gardin JM, Oberman A. Exer­cise blood pressure response and 5-year risk of elevated blood pressure in a cohort of young adults: the CARDIA study. Am J Hypertens 1994;7: 234–241. CT.

149. Fagard R, Staessen J, Amery A. Exercise blood pressure and target organ damage in essential hypertension. J Hum Hypertension 1991;5: 69–75. OS.

150. Filipovsky J, Ducimetiere P, Safar M. Prognostic significance of exercise blood pressure and heart rate in middle-aged men. Hypertension 1992; 20:337–339. OS.

151. Lauer MS, Levy D, Anderson KM, Plehn JF. Is there a relationship between exercise systolic blood pressure response and left ventricular mass? Ann Intern Med 1992;116:203–210. OS.

152. Smith DHG, Neutel JM, Graettinger WF, Myers J, Froelicher VF, Weber MA. Impact of left ventricular hypertrophy on blood pressure responses to exercise. Am J Cardiol 1992;69:225–228. OS.

153. Fagard R, Staessen J, Thijs L, Amery A. Relation of left ventricular mass and filling to exercise blood pressure and rest blood pressure. Am J Cardiol 1995;75:53–57. OS.

154. Markovitz JH, Raczynski JM, Lewis CE, Flack J, Chesney M, Chettur V, Hardin JM, Johnson E. Lack of independent relationships between left ventricular mass and cardiovascular reactivity to physical and psychological stress in the CARDIA study. Am J Hypertens 1996;9: 915–923. OS.

155. Fagard RH, Pardaens K, Staessen JA, Thijs L. Should exercise blood pressure be measured in clinical practice? J Hypertens 1998;16: 1215–1217. RV.

156. Kokkinos P, Pittaras A, Narayan P, Faselis C, Singh S, Manolis A. Exercise capacity and blood pressure associations with left ventricular mass in prehypertensive individuals. Hypertension 2007;49:55–61. OS.

157. Al’Absi M, Devereux RB, Lewis CE, Kitzman DW, Rao DC, Hopkins P, Markovitz J, Arnett DK. Blood pressure responses to acute stress and left ventricular mass. Am J Cardiol 2002;89:536–540. OS.

158. Rostrup M, Smith G, Bjornstad H, Westheim A, Stokland O, Eide I. Left ventricular mass and cardiovascular reactivity in young men. Hyperten­sion 1994;23(Suppl I):I168–I171. OS.

159. Al’Absi M, Devereux RB, Rao DC, Kitzman D, Oberman A, Hopkins P, Arnett DK. Blood pressure stress reactivity and left ventricular mass in a random community sample of African-American and Caucasian men and women. Am J Cardiol 2006;97:240–244. OS.

160. Fagard RH, Pardaens K, Staessen JA, Thijs L. Prognostic value of invasive hemodynamic measurements at rest and during exercise in hypertensive men. Hypertension 1996;28:31–36. OS.

161. Kjeldsen SE, Mundal R, Sandvik L, Erikssen G, Thaulow E, Erikssen J. Supine and exercise systolic blood pressure predict cardiovascular death in middle-aged men. J Hypertens 2001;19:1343–1348. OS.

162. Palatini P. Exaggerated blood pressure response to exercise: pathophy-siologic mechanisms and clinical relevance. J Sports Med Phys Fitness 1998;38:1–9. OS.

163. O’ Rourke MF. Principles and definitions of arterial stiffness, wave reflections and pulse pressure amplification. In Safar ME, O’Rourke MF (editors), Arterial stiffness in hypertension. Handbook of Hypertension. Elsevier; 2006.Vol 23:3–19. pp.

164. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihyper-tensive drug classes on central aortic pressure. Am J Hypertens 2004; 17:118–123.

165. Chen CH, Nevo E, Fetics B, Pak PH, Yin FC, Maughan WL, Kass DA. Esti­mation of central aortic pressure waveform by mathematical transform­ation of radial tonometry pressure. Validation of generalized transfer function. Circulation 1997;95:1827–1836.

166. Hope SA, Tay DB, Meredith IT, Cameron JD. Use of arterial transfer func­tions for the derivation of aortic waveform characteristics. J Hypertens 2003;21:1299–1305.

167. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O’Rourke M. CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee, Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: princi­pal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213–1225. RT.

168. Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006;19:214–219. RT.

169. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jonsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Associ­ation for the Study of Diabetes (EASD). Eur Heart J 2007;28:88–136. GL.

170. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813–1818. OS.

171. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D’Agostino RB, Vasan RS. Multiple biomarkers for the prediction of first major cardio­vascular events and death. N Engl J Med 2006;355:2631–2639. OS.

172. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the meta­bolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 2003;107:391–397. OS.

173. Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West Of Scotland Coronary Prevention Study. Circulation 2003;108:414–419. OS.

174. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt P. N-terminal pro-brain natriure-tic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens 2004;22: 1597–1604. OS.

175. Luft FC. Molecular genetics of human hypertension. J Hypertens 1998; 16:1871–1878. RV.

176. Melander O. Genetic factors in hypertension-what is known and what does it mean? Blood Press 2001;10:254–270. RV.

177. Cadman PE, O’Connor DT. Pharmacogenomics of hypertension. Curr Opin Nephrol Hypertens 2003;12:61–70. RV.

178. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001;104:545–556. RV.

179. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension microalbuminuria risk of ischemic heart disease. Hypertension 2000;35:898–903. OS.

180. De Leeuw PW, Ruilope LM, Palmer CR, Brown MJ, Castaigne A, Mancia G, Rosenthal T, Wagener G. Clinical significance of renal function in hyper­tensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004;164:2459–2464. RT.

181. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epide­miology and Prevention. Circulation 2003;108:2154–2169. GL.

182. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S. HOPE Study Investi­gators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286: 421–426. OS.

183. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P. Albuminuria and cardiovascular risk in hyperten­sive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003;139:901–906. OS.

184. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM, Bouter LM, Stehouwer CD. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mor­tality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 1999;19:617–624. OS.

185. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998;16:1325–1333. OS.

186. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE. Prevention of Renal, Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncar-diovascular mortality in general population. Circulation 2002;106: 1777–1782. OS.

187. National Kidney Foundation. Executive summary. Am J Kid Dis 2004; 43(Suppl. 1):S16–S33. RV.

188. Levy D, Salomon M, D’Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994;90:1786–1793. OS.

189. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561–1566. OS.

190. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114: 345–352. OS.

191. Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 1993;87(Suppl II): II56–II65. OS.

192. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarc­tion: The Rotterdam Study. Circulation 1997;96:1432–1437. OS.

193. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, Azen SP. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998;128:262–269. OS.

194. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Colla­borative Research Group. N Engl J Med 1999;340:14–22. OS.

195. Cuspidi C, Ambrosioni E, Mancia G, Pessina AC, Trimarco B, Zanchetti A. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens 2002;20:1307–1314. OS.

196. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlof B. LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292: 2343–2349. OS.

197. Fagard RH, Staessen JA, Thijs L, Celis H, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Leonetti G, Sarti C, Tuomilehto J, Webster J, Yodfat Y. Sys­tolic Hypertension in Europe (Syst-Eur) Trial Investigators. Prognostic significance of electrocardiographic voltages and their serial changes in elderly with systolic hypertension. Hypertension 2004;44:459–464. OS.

198. La Rovere MT, Pinna GD, Maestri R, Mortara A, Capomolla S, Febo O, Ferrari R, Franchini M, Gnemmi M, Opasich C, Riccardi PG, Traversi E, Cobelli F. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation 2003;107: 565–570. OS.

199. Bigger JT Jr, Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992;85: 164–171. OS.

200. Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ, for the Multicentre Post-Infarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256–262. OS.

201. Reichek N, Devereux RB. Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings. Circu­lation 1981;63:1391–1398. OS.

202. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57: 450–458. OS.

203. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W. American Society of Echocardiography’s Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Com­mittee; American Heart Association; European Association of Echocar-diography. European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr 2006;7:79–108. GL.

204. Jennings G, Wong J. Reversibility of left ventricular hypertrophy and malfunction by antihypertensy treatment. In: Hansson L, Birkenhager WH (editors). Handbook of Hypertension. Amsterdam: Else­vier Science; 1997. Vol 18, pp. 184–223. RV.

205. Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, Poisa P, Rizzoni D, Castellano M, Agabiti-Rosei E. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2004;43:731–738. OS.

206. De Simone G, Devereux RB, Koren MJ, Mensah GA, Casale PN, Laragh JH. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. Circulation 1996;93: 259–265. OS.

207. Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Pre­dictive value of systolic and diastolic function for incident congestive heart failure in the elderly: The Cardiovascular Health Study. J Am Coll Cardiol 2001;37:1042–1048. OS.

208. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ. Task Force for the Diagnosis, Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115–1140. GL.

209. Ogunyankin KO, Burggraf GW, Abiose AK, Malik PG. Validity of revised Doppler echocardiographic algorithms and composite clinical and angio-graphic data in diagnosis of diastolic dysfunction. Echocardiography 2006;23:817–828. OS.

210. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL. Systolic and diastolic heart failure in the com­munity. JAMA 2006;296:2209–2216. OS.

211. Zanchetti A, Agabiti-Rosei E, Ambrosioni E, Chiariello N, Leonetti G, Mancia G, Pessina AC, Rizzon P, Salvetti A, Trimarco B, Volpe M. Left ventricular diastolic dysfunction in a cohort of hypertensive patients attending hospital outpatient clinics in Italy, the APROS-DIADYS project. J Hypertension 2006;24(suppl 6):41. (abstract). OS.

212. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Risks for atrial fibrillation and congestive heart failure in patients >65 years of age with abnormal left ventricular diastolic relaxation. Am J Cardiol 2004; 93:54-58. OS.

213. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202. OS.

214. Bella JN, Palmieri V, Roman MJ, Liu JE, Welty TK, Lee ET, Fabsitz RR, Howard BV, Devereux RB. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults. The Strong Heart Study. Circulation 2002;105:1928-1933. OS.

215. Laukkanen JA, Kurl S, Eranen J, Huttunen M, Salonen JT. Left atrium size and the risk of cardiovascular death in middle-aged men. Arch Intern Med 2005;165:1788-1793. OS.

216. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, Carluccio E, Sardone MG, Porcellati C. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003;41: 218-223. OS.

217. Kizer JR, Bella JN, Palmieri V, Liu JE, Best LG, Lee ET, Roman MJ, Devereux RB. Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: the Strong Heart Study (SHS). Am Heart J 2006;151:412-418. OS.

218. Ciulla M, Paliotti R, Hess DB, Tjahja E, Campbell SE, Magrini F, Weber KT. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy versus ultrasonic tissue characteriz­ation. J Am Soc Echocardiogr 1997;10:657-664. OS.

219. Hoyt RM, Skorton DJ, Collins SM, Melton HE. Ultrasonic backscatter and collagen in normal ventricular myocardium. Circulation 1984;69: 775-782. OS.

220. Ciulla MM, Paliotti R, Esposito A, Diez J, Lopez B, Dahlof B, Nicholls MG, Smith RD, Gilles L, Magrini F, Zanchetti A. Different effects of antihyper­tensive therapies based on losartan or atenolol on ultrasound and bio­chemical markers of myocardial fibrosis: results of a randomized trial. Circulation 2004;110:552-557. RT

221. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P. European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002;106:2422-2427. RT.

222. Zanchetti A, Bond MG, Hennig M, Tang R, Hollweck R, Mancia G, Eckes L, Micheli D. ELSA Investigators. Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2004;22: 1201-1212. RT.

223. Zanchetti A, Agabiti Rosei E, Dal Palu C, Leonetti G, Magnani B, Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapa­mil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998;16:1667-1676. RT.

224. Hiatt WR. Medical treatment of peripheral arterial disease and claudica­tion. N Engl J Med 2001;344:1608-1621. RV.

225. Vogt MT, Cauley JA, Newman AB, Kuller LH, Hulley SB. Decreased ankle/ arm blood pressure index and mortality in elderly women. JAMA 1993; 270:465-469. OS.

226. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991;87:119-128. OS.

227. Vogt MT, McKenna M, Anderson SJ, Wolfson SK, Kuller LH. The relation­ship between ankle-arm index and mortality in older men and women. J Am Geriatr Soc 1993;41:523-530. OS.

228. Burek KA, Sutton-Tyrrell K, Brooks MM, Naydeck B, Keller N, Sellers MA, Roubin G, Jandova R, Rihal CS. Prognostic importance of lower extre­mity arterial disease in patients undergoing coronary revascularization in the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol 1999;34:716-721. OS.

229. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003;107:2864-2869. RV.

230. Laurent S, Katsahian S, Fassot C, Tropeano AI, Laloux B, Boutouyrie P. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003;34:1203–1206. OS.

231. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, Laurent S. Aortic stiffness is an independent predictor of primary coron­ary events in hypertensive patients: a longitudinal study. Hypertension 2002;39:10–15. OS.

232. Park JB, Schiffrin EL. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertension 2001;19:921–930. OS.

233. Korsgaard N, Aalkjaer C, Heagerty AM, Izzard AS, Mulvany MJ. Histology of subcutaneous small arteries from patients with essential hyperten­sion. Hypertension 1993;22:523–526.

234. Rizzoni D, Porteri E, Guelfi D, Muiesan ML, Valentini U, Cimino A, Girelli A, Rodella L, Bianchi R, Sleiman I, Agabiti-Rosei E. Structural alterations in subcutaneous small arteries of normotensive and hyper­tensive patients with non-insulin-dependent diabetes mellitus. Circula­tion 2001;103:1238–1244.

235. Schofield I, Malik R, Izzard A, Austin C, Heagerty A. Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circula­tion 2002;106:3037–3043. OS.

236. Rizzoni D, Porteri E, Boari GE, De Ciuceis C, Sleiman I, Muiesan ML, Castellano M, Miclini M, Agabiti-Rosei E. Prognostic significance of small-artery structure in hypertension. Circulation 2003;108: 2230–2235.

237. Greenland P, Gaziano JM. Clinical practice. Selecting asymptomatic patients for coronary computed tomography or electrocardiographic exercise testing. N Engl J Med 2003;349:465–473. RV.

238. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dys­function, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673–2678. OS.

239. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002;106:653–665. OS.

240. Taddei S, Salvetti A. Endothelial dysfunction in essential hypertension: clinical implications. J Hypertens 2002;20:1671–1674. RV.

241. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005;353:999–1007. OS.

242. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473–2483.

243. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global Out­comes (KDIGO). Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67:2089–2100. GL.

244. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, Seliger SL, Kestenbaum B, Psaty B, Tracy RP, Siscovick DS. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006;145:237–246. OS.

245. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardi­ovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56:2214–2219. OS.

246. Parving HH. Initiation and progression of diabetic nephropathy. N Engl J Med 1996;335:1682–1683. RV.

247. Ruilope LM, Rodicio JL. Clinical relevance of proteinuria and micro-albuminuria. Curr Opin Nephrol Hypertens 1993;2:962–967. RV.

248. Redon J, Williams B. Microalbuminuria in essential hypertension: rede­fining the threshold. J Hypertens 2002;20:353–355. RV.

249. Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D’Agostino RB, Vasan RS. Low-grade albuminuria and incidence of cardi­ovascular disease events in nonhypertensive and nondiabetic individ­uals: the Framingham Heart Study. Circulation 2005;112:969–975. OS.